$15.93
1.97% today
Nasdaq, Feb 05, 04:20 pm CET
ISIN
US24661P5008
Symbol
DCTH

Delcath Systems Inc Stock price

$16.25
+3.59 28.36% 1M
+7.93 95.31% 6M
+4.21 34.97% YTD
+11.72 258.72% 1Y
+8.86 119.89% 3Y
+3.25 25.00% 5Y
-2,508,799,983.75 100.00% 10Y
Nasdaq, Closing price Tue, Feb 04 2025
+0.80 5.18%
ISIN
US24661P5008
Symbol
DCTH
Sector

Key metrics

Market capitalization $519.57m
Enterprise Value $508.65m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 22.47
P/S ratio (TTM) P/S ratio 22.95
P/B ratio (TTM) P/B ratio 53.12
Revenue growth (TTM) Revenue growth 945.91%
Revenue (TTM) Revenue $22.64m
EBIT (operating result TTM) EBIT $-26.75m
Free Cash Flow (TTM) Free Cash Flow $-26.20m
Cash position $13.99m
EPS (TTM) EPS $-1.36
P/E forward negative
P/S forward 14.55
EV/Sales forward 14.24
Short interest 4.46%
Show more

Is Delcath Systems Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,821 stocks worldwide.

Delcath Systems Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

7x Buy
100%

Analyst Opinions

7 Analysts have issued a Delcath Systems Inc forecast:

Buy
100%

Financial data from Delcath Systems Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
23 23
943% 943%
100%
- Direct Costs 4.27 4.27
259% 259%
19%
18 18
1,774% 1,774%
81%
- Selling and Administrative Expenses 29 29
62% 62%
129%
- Research and Development Expense 16 16
9% 9%
69%
-26 -26
23% 23%
-117%
- Depreciation and Amortization 0.30 0.30
39% 39%
1%
EBIT (Operating Income) EBIT -27 -27
23% 23%
-118%
Net Profit -34 -34
24% 24%
-151%

In millions USD.

Don't miss a Thing! We will send you all news about Delcath Systems Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Delcath Systems Inc Stock News

Neutral
Business Wire
23 days ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced preliminary financial results for the fourth quarter and year-ended December 31, 2024. Preliminary Fourth Quarter and Full-Year 2024 Financial Results (unaudited) Total fo...
Neutral
Business Wire
about one month ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (the “Company” or “Delcath”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, announces that the Company granted an equity award, previously approved by the Company's Compensation Committee, as a material inducement to the employment of an individual whose employme...
Neutral
Business Wire
about one month ago
QUEENSBURY, N.Y.--(BUSINESS WIRE)--Delcath Systems, Inc. (Nasdaq: DCTH) (“Delcath” or the “Company”), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, today announced the exercise of 1.7 million Series E and E1 warrants which resulted in $16.3 million of funding. Approximately 6.6% of the warrants exercised were subject to cashless exer...
More Delcath Systems Inc News

Company Profile

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers. The company's lead product candidate is the melphalan hydrochloride for injection for use with the Delcath hepatic delivery system to administer high-dose chemotherapy to the liver. Its Phase III clinical trial products include FOCUS Trial for the patients with hepatic dominant ocular melanoma; and ALIGN Trial for intrahepatic cholangiocarcinoma. The company also offers melphalan hydrochloride under the Delcath Hepatic CHEMOSAT Delivery System for Melphalan name in Europe. The company was founded in 1988 and is headquartered in New York, New York.

Head office United States
CEO Gerard Michel
Employees 76
Founded 1988
Website www.delcath.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today